Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer

Study:

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region

Rationale:

Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy.

Purpose:

Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Head and Neck Cancer
Oral Complications
Radiation Toxicity		 Drug: cevimeline hydrochloride Phase 3

Verified by Daiichi Sankyo Inc. May, 2012

Sponsored by: Daiichi Sankyo Inc.
Information provided by: Daiichi Sankyo Inc.
ClinicalTrials.gov identifier: NCT00017511

Study Type: Interventional

Study Design: Primary Purpose: Supportive Care

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Robert Vitti, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.